ViewPoint Therapeutics’ $35 Million Series B Round Funding

Cooley advised ViewPoint Therapeutics on closing its $35 million Series B funding round led by TPG’s new $2 billion social impact fund, The Rise Fund.

The round also included participation from Novo Holdings and existing investors Biotechnology Value Fund, Mission Bay Capital, Lagunita BioSciences and the University of Michigan through its MINTS initiative, which is part of the endowment’s venture capital portfolio, and Ed Hurwitz, co-founder and chairman of ViewPoint. ViewPoint plans to use the proceeds of the financing to develop its lead product candidate, VP1-001, through clinical proof-of-concept studies in patients with cataracts and presbyopia. It also anticipates the proceeds will allow it to advance second-generation compounds from its ongoing medicinal chemistry efforts.

ViewPoint is a preclinical-stage biotechnology company passionately committed to the discovery, development and commercialization of treatments for diseases of protein misfolding, which is implicated in numerous common disorders of aging, including cataracts and presbyopia. ViewPoint Therapeutics, Inc., led by Jason Gestwicki, is based in San Francisco.

Cooley advised ViewPoint Therapeutics with a team including Mehdi Khodadad (Picture), Ryan James and Lee Redfearn.

Involved fees earner: Mehdi Khodadad – Cooley LLP; Ryan James – Cooley LLP; Lee Redfearn – Cooley LLP;

Law Firms: Cooley LLP;

Clients: ViewPoint Therapeutics, Inc.;


Author: Ambrogio Visconti